2D DIGE of the cerebrospinal fluid proteome in neurological diseases

References

• Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69(3), 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain127(Pt 7), 1463–1478 (2004).
   PubMed Web of Science ®Google Scholar
• Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med.8(4), 431–440 (1989).
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. (1), CD001447 (2007).
   PubMedGoogle Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev. (1), CD005593 (2006).
   PubMedGoogle Scholar
• Tumani H, Teunissen C, Sussmuth S, Otto M, Ludolph AC, Brettschneider J. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev. Mol. Diagn.8(4), 479–494 (2008).
   PubMed Web of Science ®Google Scholar
• Reiber H. Flow rate of cerebrospinal fluid (CSF) – a concept common to normal blood–CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci.122(2), 189–203 (1994).
   PubMed Web of Science ®Google Scholar
• Lehmensiek V, Sussmuth SD, Brettschneider J et al. Proteome analysis of cerebrospinal fluid in Guillain-Barré syndrome (GBS). J. Neuroimmunol.185(1–2), 190–194 (2007).
   PubMed Web of Science ®Google Scholar
• Lehmensiek V, Sussmuth SD, Tauscher G et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult. Scler.13(7), 840–849 (2007).
   PubMed Web of Science ®Google Scholar
• Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand.88(3), 221–223 (1993).
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Scheltens P. Use of proteomic approaches to identify disease biomarkers. Lancet Neurol.6(12), 1036–1037 (2007).
   PubMed Web of Science ®Google Scholar
• Freeman WM, Hemby SE. Proteomics for protein expression profiling in neuroscience. Neurochem. Res.29(6), 1065–1081 (2004).
   PubMedGoogle Scholar
• Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal. Bioanal. Chem.382(3), 669–678 (2005).
   PubMed Web of Science ®Google Scholar
• Unlü M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis18(11), 2071–2077 (1997).
   PubMed Web of Science ®Google Scholar
• Davidsson P, Sjogren M. Proteome studies of CSF in AD patients. Mech. Ageing Dev.127(2), 133–137 (2006).
   PubMedGoogle Scholar
• Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol. Cell. Proteomics4(12), 2000–2009 (2005).
   PubMed Web of Science ®Google Scholar
• Huang JT, Wang L, Prabakaran S et al. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol. Psychiatry13(12), 1118–1128 (2008).
   PubMed Web of Science ®Google Scholar
• Huang JT, Leweke FM, Tsang TM et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS ONE2(1), e756 (2007).
   PubMed Web of Science ®Google Scholar
• Widl K, Brettschneider J, Schattauer D et al. Erythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological disease. Neurochem. Res.32(7), 1163–1168 (2007).
   PubMed Web of Science ®Google Scholar
• Yuan X, Desiderio DM. Proteomics analysis of human cerebrospinal fluid. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.815(1–2), 179–189 (2005).
   PubMed Web of Science ®Google Scholar
• Davidsson P, Folkesson S, Christiansson M et al. Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun. Mass Spectrom.16(22), 2083–2088 (2002).
   PubMed Web of Science ®Google Scholar
• Yuan X, Desiderio DM. Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics5(2), 541–550 (2005).
   PubMed Web of Science ®Google Scholar
• Lilley KS, Friedman DB. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev. Proteomics1(4), 401–409 (2004).
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Mogel H, Lehmensiek V et al. Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem. Res.33(11), 2358–2363 (2008).
   PubMed Web of Science ®Google Scholar
• Brechlin P, Jahn O, Steinacker P et al. Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2D DIGE) facilitates the differential diagnosis of Creutzfeldt–Jakob disease. Proteomics8(20), 4357–4366 (2008).
   PubMed Web of Science ®Google Scholar
• Gharbi S, Gaffney P, Yang A et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol. Cell. Proteomics1(2), 91–98 (2002).
   PubMed Web of Science ®Google Scholar
• Becker JS, Jakubowski N. The synergy of elemental and biomolecular mass spectrometry: new analytical strategies in life sciences. Chem. Soc. Rev.38(7), 1969–1983 (2009).
   PubMed Web of Science ®Google Scholar
• Hillenkamp F, Karas M, Beavis RC, Chait BT. Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. Anal. Chem.63(24), A1193–A1203 (1991).
   PubMedGoogle Scholar
• Cottrell JS. Protein identification by peptide mass fingerprinting. Pept. Res.7(3), 115–124 (1994).
   PubMedGoogle Scholar
• Steen H, Mann M. The ABC’s (and XYZ’s) of peptide sequencing. Nat. Rev. Mol. Cell Biol.5(9), 699–711 (2004).
   PubMed Web of Science ®Google Scholar
• Rohrbough JG, Galgiani JN, Wysocki VH. The application of proteomic techniques to fungal protein identification and quantification. Ann. NY Acad. Sci.1111, 133–146 (2007).
   PubMedGoogle Scholar
• Ahmed FE. Utility of mass spectrometry for proteome analysis: part I. Conceptual and experimental approaches. Expert Rev. Proteomics5(6), 841–864 (2008).
   PubMed Web of Science ®Google Scholar
• Ahmed FE. Utility of mass spectrometry for proteome analysis: part II. Ion-activation methods, statistics, bioinformatics and annotation. Expert Rev. Proteomics6(2), 171–197 (2009).
   PubMed Web of Science ®Google Scholar
• Carrette O, Demalte I, Scherl A et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics3(8), 1486–1494 (2003).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Vanmechelen E, Van de Voorde A et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study. J. Neurol. Neurosurg. Psychiatry64(3), 298–305 (1998).
   PubMed Web of Science ®Google Scholar
• Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat. Med.13(11), 1359–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Claus A, Kassubek J, Tumani H. Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. J. Neurol.252(9), 1067–1073 (2005).
   PubMed Web of Science ®Google Scholar
• Bossuyt PM, Reitsma JB, Bruns DE et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin. Chem.49(1), 7–18 (2003).
   PubMed Web of Science ®Google Scholar
• Brazma A, Hingamp P, Quackenbush J et al. Minimum information about a microarray experiment (MIAME) – toward standards for microarray data. Nat. Genet.29(4), 365–371 (2001).
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer93(4), 387–391 (2005).
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Appel RD, Van Eyk JE et al. Guidelines for the next 10 years of proteomics. Proteomics6(1), 4–8 (2006).
   PubMed Web of Science ®Google Scholar
• Taylor CF, Paton NW, Lilley KS et al. The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol.25(8), 887–893 (2007).
   PubMed Web of Science ®Google Scholar
• Tonge R, Shaw J, Middleton B et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics1(3), 377–396 (2001).
   PubMed Web of Science ®Google Scholar
• Rozek W, Ricardo-Dukelow M, Holloway S et al. Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J. Proteome Res.6(11), 4189–4199 (2007).
   PubMed Web of Science ®Google Scholar
• Gao WM, Chadha MS, Berger RP et al. A gel-based proteomic comparison of human cerebrospinal fluid between inflicted and non-inflicted pediatric traumatic brain injury. J. Neurotrauma24(1), 43–53 (2007).
   PubMed Web of Science ®Google Scholar
• Jin T, Hu LS, Chang M, Wu J, Winblad B, Zhu J. Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients. Eur. J. Neurol.14(5), 563–568 (2007).
   PubMed Web of Science ®Google Scholar
• Qin Z, Qin Y, Liu S. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell. Mol. Neurobiol.29(2), 203–210 (2009).
   PubMed Web of Science ®Google Scholar
• Liu S, Bai S, Qin Z, Yang Y, Cui Y, Qin Y. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J. Cell. Mol. Med.13(8A), 1586–1603 (2009).
   PubMed Web of Science ®Google Scholar
• Tian XJ, Li JY, Huang Y, Xue YP. Preliminary analysis of cerebrospinal fluid proteome in patients with neurocysticercosis. Chin. Med. J. (Engl.)122(9), 1003–1008 (2009).
   PubMedGoogle Scholar
• Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand. J. Clin. Lab. Invest.37(5), 397–401 (1977).
   PubMed Web of Science ®Google Scholar
• Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin. Chim. Acta.163(3), 319–328 (1987).
   PubMed Web of Science ®Google Scholar
• Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J. Neurol. Sci.184(2), 101–122 (2001).
   PubMed Web of Science ®Google Scholar